PR94683

EAST RUTHERFORD, N.J. , March 1, 2022 /PRNewswire=KYODO JBN/ --

Cambrex, a leading global contract development and manufacturing organization

(CDMO) providing drug substance, drug product, and analytical services across

the entire drug lifecycle, today announced it is significantly expanding its

existing biopharmaceutical testing services business. The expansion includes 11

additional cGMP laboratories at Cambrex's Durham, NC facility and broadens its

service offering for large molecule and viral/cell-based therapeutics.

"We are excited to be adding to our fast-growing biopharmaceutical services

business.," said Cambrex CEO Thomas Loewald. "Building upon the strength of our

analytical team in Durham, this expansion enables us to increase our capacity

to serve the large and growing biologics market, supporting the development and

testing of a rapidly growing pipeline of large molecule therapeutics."

The expansion includes a range of new instruments supporting nanoparticle size

analysis, imaging, qPCR, fluorescent/absorbance plate readers, immunoblotting,

mass spectrometry, next-generation sequencing (NGS), chromatography capillary

electrophoresis (CE-PDA and FLD), SEC-MALS, and other compendial testing.

These new capabilities apply to a wide variety of biopharmaceutical

therapeutics, including bacteriophage and mammalian viruses, recombinant

proteins, monoclonal antibodies, and nucleic acids. Additionally, Cambrex

recently installed a new 600 MHz NMR spectrometer to enhance support for both

biopharmaceutical and small molecule programs. Combining these new capabilities

with their existing services, Cambrex is now positioned to provide analytical

services throughout the lifecycle of small and large molecule therapeutics.  

About Cambrex

Cambrex is a leading global contract development and manufacturing organization

(CDMO) that provides drug substance, drug product, and analytical services

across the entire drug lifecycle. With over 40 years of experience and a

growing team of over 2,200 experts servicing global clients from North America

and European sites, Cambrex is a trusted partner in branded and

generic markets for API and dosage form development and manufacturing.

Cambrex offers a range of specialized drug substance technologies and

capabilities, including biocatalysts. Continuous flow, controlled substances,

solid-state science, material characterization, and highly potent APIs. In

addition, Cambrex can support conventional dosage forms, including oral solids,

semi-solids, and liquids, and has the expertise to manufacturespecialty dosage

forms such as modified-release, fixed-dose combination, pediatric, bi-layer

tablets, stick packs, topicals, controlled substances, sterile and non-sterile

ointments.

For more information, visit www.cambrex.com　

Logo - https://mma.prnewswire.com/media/1723116/Cambrex_40_Years_Logo.jpg

Source: Cambrex